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Abstract: Tobacco smoking is widespread and is one of the world’s most prevalent modiﬁ  able 
risk factors for morbidity and mortality. It is important to facilitate smoking cessation better in 
order to reduce the health consequences of tobacco use. The most effective approach assisting 
smokers in their quit attempts combines both pharmacotherapy and nonpharmacological interven-
tions. This review summarizes the latest international epidemiological data available on tobacco 
use, considers the associated effects on health, and reviews existing policies against tobacco 
use. Among the interventions for smoking cessation, the three major pharmacotherapies (which 
have demonstrated efﬁ  cacy when combined with behavioral support) are discussed: nicotine 
replacement therapy (NRT), bupropion, and varenicline. As the newest pharmacotherapy made 
available in this area, particular consideration is given to varenicline, and a review of our clinical 
experience is offered.
Keywords: tobacco smoking cessation, nicotinic substitution, nicotine replacement therapy 
(NRT), bupropion, varenicline
Introduction
Approximately 1.3 billion people worldwide currently smoke cigarettes or other prod-
ucts. Yet the prevalence of smoking varies greatly among nations, with many industrial-
ized countries having seen a reduction in tobacco use, and there has been a growing shift 
in use from developed to developing countries in recent years. Approximately a third 
(35%) of men in developed countries smoke compared with almost half of the male 
population in developing nations (Shafey et al 2008). In the US in 2005, 45.1 million 
(20.8%) adults were classiﬁ  ed as current cigarette smokers. Within that population, 
the highest prevalence by age group was found in those aged 18–24 years (23.9%) and 
those aged 25–44 years (23.5%). In Canada the prevalence of current smokers over 
the age of 15 years is slightly lower at 19%, 20% among men and 17% among women 
(Health Canada 2007). At 28.6%, the prevalence of current smokers in Europe at the 
end of 2005 was higher than that recorded in North America (40% for European men 
and 18.2% for women). Within regions, however, prevalence varies widely, particularly 
among countries in Western and Eastern Europe (World Health Organization [WHO] 
2007). There is also a socioeconomic variation in smoking prevalence. A higher propor-
tion of adult smokers live below the federal poverty level than in higher socioeconomic 
groups. Variations in tobacco smoking prevalence have also been reported according 
to race, ethnicity, and education level.
The ﬁ  nancial costs of cigarette smoking are manifold. The cost to the economy 
alone in the US is estimated to be US$167 billion annually as a result of lost productiv-
ity and premature death (US$92 billion), and health-care expenditure (US$75.5 billion) 
(Centers for Disease Control and Prevention 2006). Across Europe, the economic 
burden associated with smoking in 2000 was estimated to range from  97.7 billion 
to  130.3 billion (WHO 2007).Vascular Health and Risk Management 2008:4(4) 838
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Active smoking: health 
implications
Approximately 50% of all long-term smokers die prematurely 
as a result of the adverse effects of their habit. Cigarette 
smoking is estimated to be responsible for nearly 44,000 
deaths in the US every year (18.3% of the annual national 
total of 2.4 million). As such, the American Heart Associa-
tion considers cigarette smoking to be the country’s lead-
ing preventable cause of premature death (American Heart 
Association 2008). Similarly, the World Health Report 
2002 estimated that tobacco was the leading risk factor for 
premature mortality in Europe, causing about 1.6 million 
deaths that year (WHO 2002).
In particular, tobacco use increases risk of cancer and 
respiratory and cardiovascular diseases. With 16 million cases 
of coronary heart disease (CHD) diagnosed in 2005, CHD is 
the major cause of death in the American population. It is esti-
mated that more than 90% of cardiovascular events will occur 
in individuals with at least one elevated cardiovascular risk 
factor (Greenland et al 2003), and around 8% in people with 
only borderline levels of multiple factors (Vasan et al 2005). 
Myocardial infarction (MI) risk factors include: hyperten-
sion; diabetes; abdominal obesity; dietary patterns; physical 
activity; alcohol consumption; psychosocial factors; and, in 
particular, abnormal lipids and smoking. The relative risk 
(RR)  of acute MI as a result of smoking, or an adverse lipid 
proﬁ  le, hypertension or diabetes is greater among younger 
(rather than older) individuals. Overall, current smokers face 
an almost 3-fold increase in nonfatal MI risk compared with 
that of never-smokers, irrespective of sex, geography, and 
variety of tobacco products or the type of cigarettes smoked. 
The risk has been shown to be directly proportional to the 
number of cigarettes smoked, with an odds ratio (OR) of 9.16 
(99% CI 6.18–13.58) calculated for those who smoke more 
than 40 cigarettes a day, and no threshold or plateau in the 
dose-response curve indicating that there is a level of smoking 
that could be considered to be safe (Yusuf et al 2004). 
Cigarette smokers are also 10 times more likely to develop 
peripheral vascular disease and twice as likely to suffer a 
stroke than individuals who have never smoked (Centers for 
Disease Control and Prevention 2005).
Smoking cessation, however, can successfully and 
substantially reduce the number of premature deaths related 
to the adverse effects of tobacco smoking. Although the 
beneﬁ  ts of smoking cessation as a health intervention are 
greater the earlier they are introduced, smoking cessation is 
beneﬁ  cial at any stage as it improves prognosis and quality 
of life, even after disease onset.
Public policies against tobacco 
smoking
Smoking is becoming increasingly less socially acceptable, 
and an increasing number of tobacco control policies have 
been introduced in the US and Europe in recent years. The 
implementation of anti-tobacco legislation is designed to 
minimize tobacco consumption and to create a more sup-
portive environment for those smokers who would like to 
quit. The policies address multiple aspects of tobacco use and 
the tobacco industry, including: increased prices and taxes on 
tobacco products; tobacco advertising and sponsorship bans; 
regulation of tobacco products; inclusion of stronger health 
warnings on labels; restricting the sale of tobacco products 
to minors; smoking bans on public transport and in public 
areas, such as workplaces and also restaurants, bars, and pubs 
(Hu et al 1995; Fichtenberg et al 2002).
Public health campaigns have increased the public’s 
awareness and understanding of the harmful health effects 
of both active and passive smoking. As a result, people’s atti-
tudes towards smoking are less tolerant, and there has been 
an increase in motivation and education for smokers to quit. 
There is increasing pressure from the public towards smoke-
free environments, creating a need to provide effective 
support for those smokers attempting to quit. As smoking 
cessation is becoming an important component of national 
and international tobacco control policies and programs, and 
is an effective health intervention, programs that focus on 
prevention, diagnosis, and treatment of tobacco dependence 
must be a key part of primary care (WHO 2007).
Managing smoking cessation
In a survey of 4 countries, it was found that most smokers 
would like to quit (Hyland et al 2006). It is important to 
motivate smokers to act upon these desires and to encour-
age patients to stop as quickly and as early as possible. The 
essential features of smoking cessation treatment have been 
encapsulated in the “ﬁ  ve As” (Fiore et al 2000):
1.  Ask about smoking at every opportunity.
2.  Advise all smokers to stop.
3.  Assess their willingness to stop.
4.  Assist the smoker to stop.
5. Arrange  follow-up.
However, a simpler and more patient-centered approach 
to smoking cessation treatment may be to ask the patient 
about their previous attempts to quit and to evaluate the best 
options for future attempts. This can be effective even if the 
smoker is early in the motivational cycle, as many smokers Vascular Health and Risk Management 2008:4(4) 839
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will express an interest in quitting if they are offered help 
(Pisinger et al 2005). Healthcare practitioners should also 
be mindful that most smoking cessation attempts fail and 
that patients dependent on tobacco, like those with other 
chronic diseases, need long-term support to achieve the 
ultimate goal of abstinence and to reduce tobacco-related 
health risks. The most effective methods of helping smokers 
to quit smoking combine pharmacotherapy and nonpharma-
cologic interventions (Fiore et al 2000; Lancaster et al 2000a; 
West et al 2000).
Nonpharmacologic interventions
Behavioral support is essential for the treatment of tobacco 
dependence. Health professionals should (minimally) be able 
to provide simple, brief advice (1–2 minutes) routinely to all 
smokers who use their services. Provision of more intensive 
advice (more than 20 minutes) is also useful for smokers who 
are motivated to quit, and additional reinforcement methods 
such as self-help manuals, videos or CD Roms can also be 
used. Smokers can seek support through a wide range of 
available channels, including the Internet, the telephone, and 
one-on-one or group counseling sessions.
Intensive behavioral support provided outside routine 
clinical care by appropriately trained smoking cessation 
counsellors is the most effective nonpharmacological 
intervention for smokers strongly motivated to stop smok-
ing. Various psychological models can be used, most of 
which comprise a review of the patient’s smoking history 
and their motivation to quit, identiﬁ  cation of those situa-
tions that led to relapse during previous quit attempts, and 
advice on strategies for dealing with such situations should 
they occur during future quit attempts (Coleman 2004). In 
addition, general motivational techniques or motivational 
enhancement therapy can be used to instigate behavioral 
changes. These techniques aim to change the smoker’s nor-
mal ambivalence to their habit by evaluating the importance 
of change and by reinforcing self-efﬁ  cacy. Behavioral and 
cognitive therapy can be useful to help smokers recognize, 
avoid, and cope with difﬁ  cult situations in which they are 
most likely to smoke (Fiore et al 2000; Le Foll et al 2002; 
Lancaster et al 2000b).
Smokers tend to consider health risks less than non-
smokers (Weinstein 1998), but pregnancy or severe health 
problems (eg, an MI) can lead to increased motivation to 
stop and can improve abstinence rates, especially when a 
speciﬁ  c tobacco-dependence intervention is provided. It is 
important for the clinician to tailor treatment to the indi-
vidual patient and to offer them a personalized understanding 
of their health risks by explaining the connection between 
their symptoms of disease and their smoking, and by iden-
tifying the beneﬁ  ts that will be afforded should they stop 
smoking.
Pharmacotherapy
Three types of available pharmacological interventions for 
smoking cessation have demonstrated efﬁ  cacy when used in 
conjunction with behavioral support: nicotine replacement 
therapy (NRT), bupropion, and varenicline (Fiore et al 2000; 
West et al 2000). Because no criteria are available to assess 
which pharmacotherapy will prove most effective in a given 
patient, treatment decisions are made at the discretion of the 
clinician and should take into account contraindications and 
the smoker’s history and preference.
Other medications, especially nortryptiline and clonidine, 
are considered to be effective adjunct therapy in smoking 
cessation, but they remain second-line options at this time 
(Le Foll et al 2007).
Nicotine replacement therapy
NRT aims to alleviate nicotine withdrawal symptoms and to 
reduce smokers’ desire to smoke. A variety of products are 
available (see Table 1). Those products with a shorter duration 
of action, in which blood-nicotine levels reach a peak within 
20 minutes, allow patients to tailor better their nicotine intake 
via NRT according to their needs (Silagy et al 2004; Gries 
et al 1998; Gourlay et al 1997; Benowitz et al 1997).
To optimize the efﬁ  cacy of NRT, it must be used suf-
ﬁ  ciently and correctly. Clinicians can improve efﬁ  cacy if 
they provide patients with practical advice on how to adjust 
their nicotine substitution level depending on the clinical 
signs of toxic effects or persistence of withdrawal symptoms 
(eg, depressed mood, irritability, anxiety, craving, nervous-
ness, impaired concentration). Clinicians can also calculate 
the optimal substitution dose of nicotine more precisely 
on the basis of the level of cotinine (inhaled nicotine per 
24 hours = urinary cotinine [μg/L] x 0.013) in order to 
reach full replacement of their usual nicotine concentration 
(Lagrue et al 1994; Benowitz 1996; Larramendy et al 2004). 
Accurate calculation is particularly useful when titrating 
the correct dose in more severely addicted smokers and for 
pregnant women, adolescents, and cardiovascular patients 
in whom NRT can now be prescribed (Joseph et al 1996; 
Dempsey et al 2001; McRobbie et al 2001; Meine et al 2005; 
Moolchan et al 2005).
Use of patches (for background nicotine replacement) 
and gums or tablets (for urges) seems to improve the chance Vascular Health and Risk Management 2008:4(4) 840
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Table 1 Summary of some key information relating to a selection of pharmacotherapies available for smoking cessation
Pharmacotherapy Strength Pharmacokinetic Dosage
Nicotine patch 7, 14, 21 mg
5, 10, 15 mg
Cmax: 4–9 hours According to nicotine 
absorption
Nicotine gum/tablets 2, 4 mg Cmax: 20–30 min 9–12 to 23–30/day
Nicotine inhaler 10 mg/cartridge Cmax: 20–30 min 6–16 cartridge/day
Nicotine nasal spray
Bupropion 
hydrochloride
10 mg/ml
150 mg/tab
Cmax: 10 min
Cmax: 2.5–3 hours
T1/2 : 20 hours
Steady-state: 5–8 days
8–40 doses/day
150 mg every morning 
for 6 days, then 150 mg 
twice daily
Delay of 8 hours 
between pills
Varenicline tartrate 0.5, 1 mg/tab Cmax: 3–4 hours
T1/2 :24 hours
Steady-state: 4 days
0.5 mg once daily for
3 days, then 0.5 mg twice 
daily for 4 days and then 
1 mg twice daily
for use in smoking cessation (Nomikis et al 1989; Hurt et al 
1997; Jorenby 2002). It inhibits the reuptake of both dopamine 
and norepinephrine in the central nervous system (Nomikos 
et al 1989). Its dopaminergic activity on the pleasure and 
reward pathways in the mesolimbic system and the nucleus 
accumbens could explain its success in reducing nicotine crav-
ing and the symptoms of withdrawal. It may also function as 
a nicotine acetylcholine receptor antagonist, which may be 
critical for smoking cessation (Slemmer et al 2000).
Bupropion’s effect on nicotine dependence appears to be 
quite separate from its antidepressant effect, as it has been 
shown to be effective in patients who have no depressive 
symptoms.
Insomnia, which has been reported in 30–40% of patients 
taking bupropion, can be reduced by taking the evening dose 
more than 4 hours before bed. There are also suggestions 
that bupropion increases risk of suicide, but this remains 
unproven at this time.
As treatment-emergent hypertension has been reported, 
especially when bupropion is used in combination with the 
NRT patch, it may be prudent to take into consideration 
blood pressure measurements. Bupropion is useful either as 
monotherapy or in combination with NRT products. Com-
bination therapy can be particularly relevant when dealing 
with smokers who have high levels of nicotine dependence 
and in those with a history of psychiatric problems. It can 
also be used to prevent relapse in patients who have failed 
on prior therapy (Hays et al 2001). Attenuation of weight 
of quitting successfully. Several patches can be used simulta-
neously on the skin of patients with a high level of physical 
dependence. Local skin irritation and contact sensitization can 
be reduced by moving the application site daily, and sleep distur-
bance can be decreased by removing the patch before bed. There 
are no signiﬁ  cant differences between 24-hour and 16-hour 
patches in terms of quit rates and withdrawal symptoms.
In addition to providing nicotine replacement, the NRT 
inhaler acts as a substitute for the behavioral aspect of ciga-
rette smoking, but it requires deep and frequent inhalation 
in order to replace nicotine concentrations in the blood sig-
niﬁ  cantly (Corelli et al 2006; Frishman et al 2006).
NRT should be prescribed as monotherapy initially, 
with subsequent combination therapy (consisting of vari-
ous combinations of NRT products) if monotherapy proves 
unsuccessful.
The RR of abstinence when using any form of NRT 
product is 1.58 (95% CI 1.50–1.66) relative to control. The 
RR for each product varies from 1.43 (CI 1.33–1.53) for 
nicotine gum and 1.66 (CI 1.53–1.81) for the patch, to 1.90 
(CI 1.36–2.67) for the inhaler and 2.00 (CI 1.63–2.45) for 
oral tablets. NRT products, therefore, increase the probability 
of successful cessation by 50%–70% depending on the exact 
product used (Stead et al 2008).
Bupropion
Bupropion was originally licensed as an atypical anti-depressant, 
but has been proven to be an effective non-nicotine medication Vascular Health and Risk Management 2008:4(4) 841
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gain was observed in abstinent smokers during bupropion 
treatment, and the agent may also be offered to patients who 
are concerned about post-cessation weight gain.
A meta-analysis of several trials shows that bupropion 
nearly doubles cessation rates with an OR of 1.94 (95% CI 
1.72–2.19), a similar efﬁ  cacy to NRT (Hughes et al 2007).
Varenicline
Varenicline is the most recent drug developed for speciﬁ  c 
use in smoking cessation. It has a different mechanism of 
action to the other available smoking cessation products and 
appears to be an improvement on existing treatments for 
tobacco dependence.
Pharmacology
Chemically and pharmacologically related to cytisine, vareni-
cline is a selective partial agonist of the α4β2 nicotinic receptor 
and can act like an agonist or an antagonist, depending on the 
state of the receptor. Thus it is designed to work on the same 
receptor in the brain as nicotine to help relieve the craving and 
withdrawal symptoms associated with giving up smoking, while 
at the same time block the satisfying effects of nicotine.
As a partial agonist, varenicline stimulates a moderate 
and sustained release of dopamine in the shell of the nucleus 
accumbens, thereby counteracting the low dopamine levels and 
withdrawal symptoms observed during smoking cessation. 
Furthermore its competitive binding to the nicotinic receptor 
should prevent the nicotine-induced dopaminergic activation in 
the event that the patient smokes, making it useful to decrease 
the reinforcing effects of nicotine (Coe et al 2005). Varenicline 
has also been described as a full agonist of the monomeric α7 
receptor (Mihalak et al 2006), suggesting that the relationship 
between the binding afﬁ  nity and the functional potency of var-
enicline at different receptors requires further examination.
A total treatment duration of 12 weeks is usually 
recommended (Nides et al 2006). If a patient who has managed 
to stop smoking at the end of the treatment period lacks 
conﬁ  dence about remaining abstinent, it is worth considering 
treatment continuation, bearing in mind the high smoking 
relapse rates. Results of a long-term safety study indicate that 
varenicline is well tolerated and has a favorable safety proﬁ  le 
for administration of up to 1 year (Williams et al 2007).
Varenicline is highly absorbed after oral administration; it 
is not affected by food intake and is not signiﬁ  cantly bounded 
to protein. Less than 10% of the compound is metabolized 
in the liver and it is primarily excreted (unchanged) in the 
urine. However, precautions should be taken with patients 
who have severe renal impairment. It has a half-life of 
17–30 hours (Faessel et al 2006a, b; Obach et al 2006). No 
signiﬁ  cant drug-drug interactions have so far been identiﬁ  ed 
with the use of varenicline, and there do not appear to be 
contraindications at this time.
Efﬁ  cacy
Several double-blind, randomized, controlled clinical trials 
(RCT) of varenicline have been carried out involving almost 
Duration Adverse effects 
(not exhaustive)
Contraindications/Precautions 
(not exhaustive)
3 months
Maintenance up to
12 months
Local skin reaction, insomnia Hairless, clean, dry, low friction skin 
areas
Up to 12 weeks Mouth soreness, dyspepsia, 
jaw ache, hiccups,
Intermittently, slowly chewed
To avoid acidic drink for 15 min 
before use
Up to 6 months Mouth and throat irritation
3–6 months
7–9 weeks
Maintenance up to 6 months
Nasal irritation
Insomnia, dry mouth, seizure (0.1%) History of seizure, eating disorders, 
serious head trauma, adolescents 
below 18 years and pregnant 
women, concomitant intake of 
monoamine oxidase inhibitors
12 weeks
Maintenance up to a further 
12 weeks (if required)
Nausea (30%), insomnia, abnormal 
dreams, headache
Adolescents below 18 years and 
pregnant womenVascular Health and Risk Management 2008:4(4) 842
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5,000 smoking cessation participants, 2,451 of whom 
received varenicline (Cahill et al 2007). One relapse pre-
vention trial has been carried out, and while all cessation 
trials assessed varenicline against placebo, 3 also included 
a bupropion experimental arm. The period of follow-up in 
the cessation trials was 12, 24, and 52 weeks.
The RCTs demonstrated that varenicline has superior 
efﬁ  cacy compared with placebo and bupropion. The pooled 
OR for validated continuous abstinence at 12 months for 
varenicline versus placebo was 3.22 (95% CI 2.43–4.27) and 
1.66 (95% CI 1.28–2.16) for varenicline versus bupropion 
(Gonzales et al 2006; Jorenby et al 2006; Nides et al 2006; 
Oncken et al 2006). The relapse prevention trial concluded 
that varenicline offers signiﬁ  cant beneﬁ  t versus placebo 
with an OR for validated continuous abstinence of 1.34 
(95% CI 1.06–1.69) (Tonstad et al 2006).
A recent study has also suggested that varenicline is 
more effective than NRT in short-term routine treatment 
of tobacco dependence, with a beneﬁ  t similar to that seen 
for varenicline over bupropion in the previous RCTs. The 
study also demonstrated that the efﬁ  cacy of varenicline 
was similar in both patients with and without mental ill-
ness (Stapleton et al 2008). The efﬁ  cacy and safety of 
varenicline used in combination with bupropion or NRT is 
not recommended at this time as no trials in this area have 
yet been carried out.
Safety
In clinical trials, varenicline exhibited a favorable safety pro-
ﬁ  le compared with placebo and was well tolerated at doses 
up to (and including) 2 mg/day in healthy adult smokers 
(see Table 1). The nausea was generally mild to moderate 
and often diminished over time or in response to a dose 
reduction, or administration with food (Gonzales et al 2006; 
Jorenby et al 2006). Although the side effects associated with 
treatment were relatively common, there was no difference in 
patients withdrawing from treatment between the varenicline 
and placebo study arms. No treatment-related deaths were 
reported in any of the RCTs (Cahill et al 2007).
Suicidal ideation and suicide attempts have recently 
been reported in patients who stopped smoking while 
taking varenicline. Although it is difﬁ  cult to establish 
whether these events are attributable to varenicline or the 
smoking cessation attempt itself (which can be associated 
with depressed mood and sometimes suicidal thoughts) the 
European regulatory authority recommend that: “clinicians 
should be aware of the possible emergence of signiﬁ  cant 
depressive symptomatology in patients undergoing a 
smoking cessation attempt, and should advise patients 
accordingly” (Pﬁ  zer 2008).
Local tobacco smoking cessation 
management
Tobacco smoking is a chronic, relapsing medical condition 
that requires long-term management. As there are numerous 
time constraints placed on physicians, patients should be 
offered the option of being referred to a specialist smoking 
cessation service. In our treatment program, behavioral sup-
port is given in combination with pharmacological therapy 
and clinical decisions are made with reference to published 
literature (for choice of therapy, optimum dose) and the 
patient’s medical history. As reported in several recommenda-
tions, the initial counseling session is scheduled to be long 
enough to carry out a thorough interview of the patient and to 
develop a solid treatment plan. In our center, the ﬁ  rst patient 
session requires 60 minutes. As follow-up is critical to the 
success of treatment, provision is made to ensure smokers 
who want to give up receive regular support sessions, which 
are either carried out face-to-face or over the phone.
Because there are no clear-cut criteria to identify whether 
a patient will beneﬁ  t from a particular therapy, the medication 
is selected for each patient with full consideration of: their 
current medical conditions; contraindications and potential 
adverse effects of each medication; their individual prefer-
ence for a given treatment; previous use of smoking cessation 
aids; level of tobacco dependence, and any concerns about 
weight gain. All smokers who have previously relapsed 
when attempting to quit are questioned about their prior use 
of pharmacotherapy and their perceptions of the treatment 
options. Even light smokers and those who smoke socially 
who have failed in previous attempts to quit can beneﬁ  t from 
pharmacotherapy.
In patients who voice positive experiences with a given 
product, it may be appropriate to prescribe treatment with the 
same agent, but with consideration given to increasing the 
dose, frequency, or duration of therapy. However, in patients 
who report negative experiences with a particular agent, an 
alternative treatment choice should be selected. There is cur-
rently no evidence to indicate that one medication is the most 
effective for all the smokers attempting to quit.
NRT in its various formulations remains a well-tolerated 
and effective approach to aiding smoking cessation. It is 
the only drug treatment available for pregnant women and 
adolescents who wish to stop smoking but who have failed 
previously and who have experienced urges and withdrawal 
symptoms. By employing the concept of therapeutic drug Vascular Health and Risk Management 2008:4(4) 843
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monitoring, urinary cotinine concentrations are used in 
these patients to tailor the nicotine replacement dose so that 
it approaches full replacement of the nicotine that would 
normally be inhaled through smoking. By achieving the 
correct target blood concentration, pharmacotherapy can 
be optimized.
It may be appropriate to use higher doses of nicotine 
replacement products in heavy smokers to relieve their 
nicotine withdrawal symptoms sufﬁ  ciently (eg, use multiple 
patches at one time). In our clinic, one form of smoking ces-
sation aid is seldom used alone; rather NRT patches tend to 
be used alongside self-administered forms of NRT, especially 
in patients who are unable to stop smoking using a single, 
ﬁ  rst-line therapy. Use of any short-acting NRT product is 
recommended as often as is necessary in order to control 
intermittent withdrawal symptoms or cravings. Owing to the 
central nervous system tolerance that most smokers have to 
nicotine, over-replacement is rare.
As NRT requires frequent dosing, or non-traditional routes 
of administration, time is taken to explain the proper use of each 
product to patients. It is important to schedule follow-up ofﬁ  ce 
visits or phone calls to monitor response to treatment. Although 
several durations of treatment have been proposed, no optimal 
length of treatment has been clearly established and treatment 
should be continued as long as is determined necessary for 
each patient. Treatment duration, for example, may need to 
be longer in those who are heavily dependent on tobacco. In 
pregnant women who have previously failed to quit smoking 
with the support of behavioral therapy, NRT is proposed in the 
acute forms, eg, gums, tablets, or inhaler. If necessary a patch 
can be used, but it is recommended that it is removed before 
sleep to minimize exposure of the fetus to nicotine. The same 
advice would apply to women who are breast-feeding.
Although NRT remains widely used for smoking ces-
sation, some people prefer a treatment that does not use 
nicotine. Bupropion provides smokers with an alternative 
treatment option, especially if they are found to be intoler-
ant to varenicline. For smokers concerned about potential 
weight gain, it might be preferable to use bupropion as it 
has been shown to offer the greatest attenuation of weight 
gain during treatment. Buproprion is combined with NRT 
on a patient-by-patient basis. For patients with more severe 
nicotine dependence, more than 2 products are often used 
simultaneously.
Varenicline offers a new option for smoking cessation 
and problems of relapse. It could be a ﬁ  rst-line option for 
tobacco smoking cessation if the patient expresses a particular 
preference, and it is particularly useful in smokers who cannot 
tolerate adverse events related to bupropion or NRT, in 
those in whom these medications are contraindicated, and 
in patients who have already tried and failed on other smok-
ing cessation pharmacotherapies. Furthermore, the mixed 
agonist-antagonist effects of varenicline appear to reduce the 
psychogenic rewards associated with smoking, while also 
relieving nicotine craving and withdrawal symptoms during 
abstinence.
As successful smoking cessation is improved with adequate 
support, smokers prescribed varenicline receive a patient 
support plan that they can customize as they try to quit to 
help identify and address their individual behavioral triggers. 
Varenicline should not be prescribed in addition to other smok-
ing cessation medications. The treatment is easy for patients 
who have difﬁ  culty adhering to multiple doses of medications 
throughout the day, and is also attractive to patients who desire 
a simpliﬁ  ed regimen. Apart from the nausea, which tends to 
pass or can be minimized through dose reduction and advice 
on eating, varenicline is usually well tolerated. Patients at our 
clinic are advised to take varenicline with a glass of water and 
after, or during, a meal to reduce such side effects. It is also 
recommended that the second pill is taken at dinner rather than 
before bed in order to reduce insomnia and avoid disturbed 
dreams. At the end of the treatment period, therapy tends to be 
extended in patients who have only recently managed to quit, 
in whom the quit attempt has not stabilized, or in those who 
have experienced minor relapses.
Conclusion
Tobacco smoking is highly prevalent throughout the world 
and is, perhaps, the greatest modifiable risk factor for 
increased morbidity and mortality. Smoking cessation is 
associated with immediate and long-term health beneﬁ  ts, 
resulting in improved general health and a reduced risk 
of smoking-related diseases. As physicians tend to deal 
with most smokers fairly regularly, they have substantial 
opportunity to inﬂ  uence their smoking behavior, and are in a 
unique position to be able to help with treatment. The likeli-
hood that a smoker will be successful in their quit attempt 
depends on several factors, at the core of which is their moti-
vation. If they are not motivated to quit, an important step 
is to devise strategies to increase their willingness to give 
up and education should be given on the impacts smoking 
can have on health. As such, health professionals should be 
familiar with smoking cessation strategies and should promote 
cessation as an effective health intervention to patients who 
smoke. All physicians should ensure that they are aware of 
the different treatment options available, and they should offer Vascular Health and Risk Management 2008:4(4) 844
Galanti
these regularly to their patients. Although medications can be 
effective in reducing withdrawal symptoms and improving 
treatment outcomes, a combination of pharmacotherapy and 
behavioral counseling is more likely to increase abstinence 
rates. Several medications are available with demonstrated 
efﬁ  cacy is helping smokers to quit: NRT, bupropion, and 
varenicline. As reported in the literature, varenicline seems 
to be the most effective treatment option currently available, 
and could be prescribed according to the patient’s preference 
and medical history.
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